Terms: = Ovarian cancer AND CARS, P49589, 833, ENSG00000110619
98 results:
1. Quantification of Unencapsulated Drug in Target Tissues Demonstrates Pharmacological Properties and Therapeutic Effects of Liposomal Topotecan (FF-10850).
Kimura T; Okada K; Morohashi Y; Kato Y; Mori M; Kato H; Matsumoto T; Shimoyama S
Pharm Res; 2024 Apr; 41(4):795-806. PubMed ID: 38536615
[TBL] [Abstract] [Full Text] [Related]
2. Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions.
Sajman J; Yakovian O; Unger Deshet N; Almog S; Horn G; Waks T; Globerson Levin A; Sherman E
Cells; 2023 Sep; 12(18):. PubMed ID: 37759484
[TBL] [Abstract] [Full Text] [Related]
3. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory ovarian cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial.
Holloway RW; Mendivil AA; Kendrick JE; Abaid LN; Brown JV; LeBlanc J; McKenzie ND; Mori KM; Ahmad S
JAMA Oncol; 2023 Jul; 9(7):903-908. PubMed ID: 37227734
[TBL] [Abstract] [Full Text] [Related]
5. Chimeric Antigen Receptor T-cell Therapy in cancer: A Critical Review.
Sharma R; Suravarjhula L; Banerjee M; Kumar G; Kumar N
Curr Drug Res Rev; 2023; 15(3):241-261. PubMed ID: 36825696
[TBL] [Abstract] [Full Text] [Related]
6. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
7. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
[TBL] [Abstract] [Full Text] [Related]
8. Computed Tomographic Radiomics in Differentiating Histologic Subtypes of Epithelial ovarian Carcinoma.
Wang M; Perucho JAU; Hu Y; Choi MH; Han L; Wong EMF; Ho G; Zhang X; Ip P; Lee EYP
JAMA Netw Open; 2022 Dec; 5(12):e2245141. PubMed ID: 36469315
[TBL] [Abstract] [Full Text] [Related]
9. Application of enhanced computed tomography-based radiomics nomogram analysis to differentiate metastatic ovarian tumors from epithelial ovarian tumors.
Zhang A; Hu Q; Ma Z; Song J; Chen T
J Xray Sci Technol; 2022; 30(6):1185-1199. PubMed ID: 36189526
[TBL] [Abstract] [Full Text] [Related]
10. CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.
Cribioli E; Giordano Attianese GMP; Coukos G; Irving M
Front Immunol; 2022; 13():951143. PubMed ID: 35990626
[TBL] [Abstract] [Full Text] [Related]
11. Does Combing O-RADS US and CA-125 Improve Diagnostic Accuracy in Assessing Adnexal Malignancy Risk in Women With Different Menopausal Status?
Wu M; Wang Q; Zhang M; Cao J; Chen Y; Zheng J; Luo L; Su M; Lin X; Kuang X; Zhang X
J Ultrasound Med; 2023 Feb; 42(3):675-685. PubMed ID: 35880406
[TBL] [Abstract] [Full Text] [Related]
12. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.
Matsuzaki J; Lele S; Odunsi K; Tsuji T
Oncoimmunology; 2022; 11(1):2020983. PubMed ID: 35003898
[TBL] [Abstract] [Full Text] [Related]
13. Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities.
Xu Y; Jiang J; Wang Y; Wang W; Li H; Lai W; Zhou Z; Zhu W; Xiang Z; Wang Z; Zhu Z; Yu L; Huang X; Zheng H; Wu S
Front Immunol; 2021; 12():725330. PubMed ID: 34386017
[TBL] [Abstract] [Full Text] [Related]
14. Chimeric Antigen Receptor Design and Efficacy in ovarian cancer Treatment.
Terlikowska KM; Dobrzycka B; Terlikowski SJ
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800608
[TBL] [Abstract] [Full Text] [Related]
15. Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery.
Li S; Zhu Z
J Ovarian Res; 2020 Aug; 13(1):91. PubMed ID: 32772926
[TBL] [Abstract] [Full Text] [Related]
16. SJI 2020 special issue: A catalogue of ovarian cancer targets for CAR therapy.
Benard E; Casey NP; Inderberg EM; Wälchli S
Scand J Immunol; 2020 Oct; 92(4):e12917. PubMed ID: 32557659
[TBL] [Abstract] [Full Text] [Related]
17. The Accuracy of Single MicroRNAs in Peripheral Blood to Diagnose ovarian cancer: An Updated Meta-Analysis.
Cui Y; Hong S; Zhu X
Dis Markers; 2020; 2020():1075942. PubMed ID: 32025275
[TBL] [Abstract] [Full Text] [Related]
18. Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against ovarian cancer.
Leong L; Tan HL; Cua S; Yong KSM; Chen Q; Choo A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936170
[TBL] [Abstract] [Full Text] [Related]
19. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.
Jin L; Tao H; Karachi A; Long Y; Hou AY; Na M; Dyson KA; Grippin AJ; Deleyrolle LP; Zhang W; Rajon DA; Wang QJ; Yang JC; Kresak JL; Sayour EJ; Rahman M; Bova FJ; Lin Z; Mitchell DA; Huang J
Nat Commun; 2019 Sep; 10(1):4016. PubMed ID: 31488817
[TBL] [Abstract] [Full Text] [Related]
20. Basing on uPAR-binding fragment to design chimeric antigen receptors triggers antitumor efficacy against uPAR expressing ovarian cancer cells.
Wang L; Yang R; Zhao L; Zhang X; Xu T; Cui M
Biomed Pharmacother; 2019 Sep; 117():109173. PubMed ID: 31387176
[TBL] [Abstract] [Full Text] [Related]
[Next]
